Vancomycin PO

C. diff Risk


Oral Bioavailability


Approximate Cost

Spectrum Of Activity


125mg po QID for 10-14 days

Intra-colonic dose 500mg in 100mL of NS by rectal enema q6h

General Information

Common Usage

Only indication is in the therapy of C. difficile infection, particularly recurrent or severe disease

Additional Information

No oral absorption. May increase vancomycin resistant enterococci colonization in the gut


Antimicrobial class: glycopeptide

Pregnancy category: B

Average serum half life: 0.0

Biliary penetration: None

CSF penetration: None

Lung penetration: None

Urine penetration: None